/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Cardiol Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.955 0.0159(1.59%) CRDL at 04 Dec 2025 04:28 PM Drug Manufacturers - Specialty & Generic
Lowest Today 0.8816
Highest Today 0.96215
Today’s Open 0.91495
Prev. Close 0.9294
52 Week High 1.59
52 Week Low 0.77
Day’s Range: Low 0.8816 High 0.96215
52-Week Range: Low 0.77 High 1.59
1 day return -
1 Week return -9.22
1 month return -10.51
3 month return -15.32
6 month return -34.2
1 year return -35.77
3 year return +80.03
5 year return -
10 year return -

Institutional Holdings

Tejara Capital Ltd 3.90

AdvisorShares Investments, LLC 1.02

AdvisorShares Pure Cannabis ETF 0.67

Lion Street Advisors, LLC 0.41

Mmcap International Inc. Spc 0.35

CAMBRIDGE Invest RESEARCH ADVISORS, INC. 0.25

Envestnet Asset Management Inc 0.22

UBS Group AG 0.17

Knoll Capital Management LP 0.12

We Are One Seven, LLC 0.12

Morgan Stanley - Brokerage Accounts 0.12

Atria Investments LLC 0.12

Cetera Investment Advisers 0.07

Goldman Sachs Group Inc 0.07

Fidelity Nasdaq Composite Index 0.06

Geode Capital Management, LLC 0.06

Bank of Montreal 0.06

BMO Capital Markets Corp. 0.06

iShares S&P/TSX Small Cap ETF 0.06

Marble Harbor Investment Counsel, LLC 0.05

Bank of America Corp 0.03

Mercer Global Advisors Inc. 0.03

JONES FINANCIAL COMPANIES LLLP 0.03

Ninepoint Alternative Health A 0.01

Market Status

Strong Buy: 1

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 92.94 M

PB Ratio 13.7779

PE Ratio 0.0

Enterprise Value 84.11 M

Total Assets 31.86 M

Volume 881060

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:78760 0.1M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:78760 0.1M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-28006293 -28.0M, FY22:-30930647 -30.9M, FY21:-31638244 -31.6M, FY20:-20640935 -20.6M, FY19:-13684023 -13.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:-61908 -0.1M

Quarterly Net worth Q3/2025:-9964281 -10.0M, Q2/2025:-8354371 -8.4M, Q1/2025:-8287653 -8.3M, Q3/2024:-12728484 -12.7M, Q2/2024:-6590873 -6.6M

Fund house & investment objective

Company Information Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Organisation Drug Manufacturers - Specialty & Generic

Employees 18

Industry Drug Manufacturers - Specialty & Generic

CEO Mr. David G. Elsley MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow